PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors

Abstract Background Programmed death-ligand 1 (PD-L1) inhibitors has emerged as a first-line therapeutic strategy for advanced small cell lung cancer (SCLC), which can stimulate T-cell activation, thereby preventing tumor avoidance of immunologic surveillance, whereas, proton pump inhibitors (PPIs)...

Description complète

Détails bibliographiques

Auteurs principaux:	Sisi Zhang, Jing Tian, Xinwei Wang, Chengxin Liu
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2023-11-01
Collection:	BMC Pulmonary Medicine
Sujets:	Immune checkpoint inhibitors PD-L1 inhibitors Immunotherapy Proton pump inhibitors Progression free survival Overall survival
Accès en ligne:	https://doi.org/10.1186/s12890-023-02754-4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!